Trial Profile

A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Saftey and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brexanolone (Primary)
Indications Postnatal depression
Focus Registrational; Therapeutic Use
Sponsors Lipocine

Most Recent Events

26 Jun 2025 According to a Lipocine media release, the Company will host a virtual research and development (R&D) investor event. The Company will provide a clinical, regulatory, and development update, including further details on the Phase 3 trial.
26 Jun 2025 According to a Lipocine media release, the Company anticipates using the data from this Phase 3 trial to support an NDA submission of LPCN 1154 for PPD in mid-2026
26 Jun 2025 According to a Lipocine media release, first patients has been dosed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com